Corbus Therapy Anabasum Reduces Acute Pulmonary Exacerbations by Up to 75% in CF Patients
Corbus Pharmaceuticals recently reported that its Phase 2 clinical trial examining multiple doses of anabasum (formerly known as JBT-101 or Resunab) compared to placebo in patients with cystic fibrosis (CF) achieved the trial’s primary endpoint demonstrating an acceptable safety and tolerability profile at all doses, with no serious or severe adverse…